Table 1.
Demographic characteristics among participants who reported pregnancy and were considered exposed to study drugs
| Characteristic | Regimen 3HP (n = 31) n (%) |
Regimen 9H (n = 56) n (%) |
||
|---|---|---|---|---|
| Age, median (IQR) | 23 (21–30) | 25 (21–29) | ||
| Enrollment site | ||||
| Brazil | 2 (6.9) | 1 (1.8) | ||
| Hong Kong | 0 (0) | 0 (0) | ||
| Peru | 0 (0) | 0 (0) | ||
| South Africa | 0 (0) | 0 (0) | ||
| Spain | 0 (0) | 0 (0) | ||
| United States/Canada | 29 (93.5) | 55 (98.2) | ||
| Race | ||||
| American Indian/Alaskan Native | 0 (0) | 0 (0) | ||
| Asian/Pacific Islander | 6 (19.4) | 9 (16.1) | ||
| Black | 3 (9.7) | 9 (16.1) | ||
| Other | 1 (3.2) | 1 (1.8) | ||
| White | 21 (67.7) | 37 (66.1) | ||
| Alcohol | ||||
| No | 19 (61.3) | 33 (58.9) | ||
| Use | 11 (35.5) | 22 (39.3) | ||
| Abuse | 1 (3.2) | 1 (1.8) | ||
| Unknown | 0 (0) | 0 (0) | ||
| LTBI treatment* | ||||
| Contact | 19 (61.3) | 40 (71.4) | ||
| Fibrosis | 2 (6.5) | 1 (1.8) | ||
| HIV positive | 0 (0) | 1 (1.8) | ||
| LTBI (+) | 2 (6.5) | 0 (0) | ||
| TST converter | 8 (25.8) | 14 (25) | ||
| Education | ||||
| High School | 19 (61.3) | 33 (58.9) | ||
| <High School | 12 (38.7) | 23 (41.1) | ||
| Unknown | 0 (0) | 0 (0) | ||
| Ethnic origin | ||||
| Non–United States/Canada | 2 (6.5) | 1 (1.8) | ||
| United States/Canada: Hispanic | 15 (48.3) | 31 (55.4) | ||
| United States/Canada: non-Hispanic | 14 (45.2) | 24 (42.9) | ||
| HIV infection | ||||
| No | 20 (64.5) | 29 (51.8) | ||
| Unknown | 11 (35.5) | 26 (46.4) | ||
| Yes | 0 (0) | 1 (1.8) | ||
| IDU history† | ||||
| No | 31 (100) | 56 (100) | ||
| Yes | 0 (0) | 0 (0) | ||
| Unknown | 0 (0) | 0 (0) | ||
| Jail | ||||
| No | 31 (100) | 56 (100) | ||
| Yes | 0 (0) | 0 (0) | ||
| Current smoker | ||||
| No | 24 (77.4) | 47 (83.9) | ||
| Yes | 7 (22.6) | 9 (16.1) | ||
| Unemployed | ||||
| No | 25 (80.6) | 51 (91.1) | ||
| Yes | 6 (19.4) | 5 (8.9) | ||
| Homeless | ||||
| No | 31 (100) | 56 (100) | ||
| Yes | 0 (0) | 0 (0) | ||
Definition of abbreviations: 3HP = 12-dose once-weekly regimen of isoniazid (900 mg) plus rifapentine (900 mg); 9H = 9-month daily isoniazid (300 mg); HIV = human immunodeficiency virus; IDU = intravenous drug use; IQR = interquartile range; LTBI = latent tuberculosis infection; TST = Tuberculin Skin Test.
*
Subjects were counted only once in the order presented. The total number of HIV-infected persons who were enrolled in the study is listed separately in this table.
†
Intravenous drug use ever.